


# Nexus AG: VERY STRONG SALES AND EARNINGS INCREASE IN THE THIRD QUARTER 2022

Donaueschingen, 08/11/2022: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 10% and EBIT by approx. 24% in the first nine months of 2022. As a result, the continually positive development of sales and earnings of the last years could be continued.


Sales improved from KEUR 137,223 to KEUR 150,790 (+9.9%) in the first nine months 2022. The international share of total business volume was 47.5% (9M-2021: 46.1%) and amounted to KEUR 71,551 compared to KEUR 63,268 (9M-2021).

The consolidated surplus rose very sharply by 24.6% to KEUR 13,845 (9M-2021: KEUR 11,110), and consolidated earnings before interest and taxes (EBIT) rose by 24.1% to KEUR 18,794 (9M-2021: KEUR 15,140); EBITA increased by 19.9% from KEUR 18,639 (9M-2021) to KEUR 22,351, and EBITDA increased by 13.2% to KEUR 31,236 (9M-2021 KEUR 27,605).

Cash flow from operating activities amounted to KEUR 30,948 (9M 2021: KEUR 24,727) in the first nine months of the year 2022, which is 25.2 % higher than in the previous year.



As of 30/09/2022, the company had cash resources at its disposal in the amount of KEUR 109,783 (31/12/2021: KEUR 26,172). Nexus AG had equity capital amounting to KEUR 234,931 as of 30/09/2022 (31/12/2021: KEUR 142,403). Consequently, the equity capital rate is 70.4% (31/12/2021: 57.6%).



The detailed quarterly report can be found on our homepage at:  
<https://www.nexus-ag.de/unternehmen/investor-relations>

## About Nexus AG

Nexus AG develops and sells software solutions for the international healthcare market. With our core Hospital Information System (NEXUS / HIS) and integrated diagnostic modules (NEXUS / DIS), we have a unique product range, which can cover almost all functional requirements of hospitals, psychiatric institutions, rehabilitation facilities and diagnostic centers within our own product families. The focus of product development is on easy-to-use process support that increases efficiency and safety in patient treatment. NEXUS employs approx. 1,650 people, is present in seven European countries with its own sites and serves customers in an additional 23 countries via certified dealers. Thanks to continuously growing demand for NEXUS products, we have been able to build up a large customer base in recent years and regularly show increases in sales and results.